Humacyte, Inc. (NASDAQ:HUMA) Short Interest Up 58.7% in June

Humacyte, Inc. (NASDAQ:HUMA) saw a significant growth in short interest in June. As of June 30th, there was short interest totalling 8,250,000 shares, a growth of 58.7% from the June 15th total of 5,200,000 shares. Approximately 9.0% of the company’s stock are short sold. Based on an average daily volume of 2,760,000 shares, the days-to-cover ratio is currently 3.0 days.

Humacyte Stock Performance

NASDAQ:HUMA opened at $6.99 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 8.37 and a quick ratio of 8.37. The business has a fifty day simple moving average of $6.18 and a two-hundred day simple moving average of $4.34. Humacyte has a 1 year low of $1.96 and a 1 year high of $9.97. The company has a market capitalization of $832.40 million, a P/E ratio of -6.87 and a beta of 1.51.

Humacyte (NASDAQ:HUMA) last released its earnings results on Friday, May 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). On average, analysts expect that Humacyte will post -0.95 earnings per share for the current year.

Analysts Set New Price Targets

HUMA has been the topic of a number of recent analyst reports. Benchmark reiterated a “buy” rating and set a $15.00 price target on shares of Humacyte in a report on Tuesday, July 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $7.00 price target on shares of Humacyte in a report on Tuesday, July 2nd. Finally, Piper Sandler reiterated a “neutral” rating and set a $4.00 price target on shares of Humacyte in a report on Tuesday, March 26th.

Insider Activity

In other news, COO Heather Ledbetter Prichard sold 188,886 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $8.14, for a total value of $1,537,532.04. Following the transaction, the chief operating officer now owns 2,625 shares in the company, valued at $21,367.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, COO Heather Ledbetter Prichard sold 188,886 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $8.14, for a total value of $1,537,532.04. Following the transaction, the chief operating officer now owns 2,625 shares in the company, valued at $21,367.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Laura E. Niklason sold 809,786 shares of the firm’s stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $7.91, for a total value of $6,405,407.26. Following the completion of the transaction, the chief executive officer now owns 5,381,354 shares in the company, valued at approximately $42,566,510.14. The disclosure for this sale can be found here. Over the last 90 days, insiders have purchased 54,412 shares of company stock worth $369,107 and have sold 1,628,820 shares worth $12,464,121. Corporate insiders own 23.10% of the company’s stock.

Hedge Funds Weigh In On Humacyte

Several hedge funds have recently made changes to their positions in HUMA. Tower Research Capital LLC TRC raised its stake in shares of Humacyte by 261.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,989 shares of the company’s stock valued at $26,000 after purchasing an additional 6,504 shares during the period. Whittier Trust Co. of Nevada Inc. bought a new stake in shares of Humacyte during the 4th quarter valued at $28,000. Victory Capital Management Inc. bought a new stake in shares of Humacyte during the 4th quarter valued at $29,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Humacyte by 350.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,986 shares of the company’s stock valued at $34,000 after purchasing an additional 9,325 shares during the period. Finally, Kovitz Investment Group Partners LLC bought a new stake in shares of Humacyte during the 4th quarter valued at $35,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.